🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Mettmann
Clinical trial register · Germany

Clinical Trials in Mettmann, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 1584 Hamburg 889 Essen 760 Dresden 707 Heidelberg 627
Narrow the registerReset
Recruitment status
Phase
Site location
Berlin1584 Hamburg889 Essen760 Dresden707 Heidelberg627
All 635 locations
Target enrolment
to

Trials with a site in Mettmann

11 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
NCT07028853Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
Pfizer
Phase 3
1,000
Heidelberg, Nürtingen, Ulm, Mettmann, Lübeck, Berlin, Düsseldorf, Hamburg
2025-09-28
Active, closed
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
NCT06551324Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Pfizer
Phase 3
600
Nürtingen, Tübingen, Mettmann, Münster, Hamburg
2024-10-21
Active, closed
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
NCT06211764Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC
Phase 3
272
Cologne, Halle, Leverkusen, Lübeck, Mettmann, München
2024-04-09
Active, closed
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
NCT05714202Bladder Cancer
Janssen Research & Development, LLC
Phase 3
1,135
Cologne, Duisburg, Erlangen, Essen, Frankfurt am Main, Freiburg im Breisgau, Markkleeberg, Mettmann
2023-03-23
Active, closed
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
NCT05316155Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC
Phase 1/2
235
Dresden, Duisburg, Frankfurt am Main, Herne, Mettmann, Münster, Ulm
2022-04-11
Recruiting
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
NCT04752722Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ, Non-muscle Invasive Bladder Cancer
enGene, Inc.
Phase 1/2
350
Cologne, Duisburg, Erlangen, Mettmann, Nürtingen, Tübingen
2021-04-22
Active, closed
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
NCT04640623Urinary Bladder Neoplasms
Janssen Research & Development, LLC
Phase 2
220
Cologne, Duisburg, Herne, Markkleeberg, Mettmann, Münster, Nuremberg, Nürtingen
2020-12-18
Active, closed
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency
NCT04493853Hormone-Sensitive Prostate Cancer
AstraZeneca
Phase 3
1,012
Berlin, Duisburg, Hamburg, Herne, Mettmann, Münster, Nuremberg, Nürtingen
2020-07-13
Active, closed
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
NCT03706365Prostate Cancer
Eli Lilly and Company
Phase 2/3
393
Nürtingen, Tübingen, Holzminden, Cologne, Mettmann, Münster, Wesel, Leipzig
2018-11-26
Active, closed
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
NCT03732820Metastatic Castration-resistant Prostate Cancer
AstraZeneca
Phase 3
895
Bergisch Gladbach, Bremen, Cologne, Duisburg, Freiburg im Breisgau, Heinsberg, Mettmann, Nuremberg
2018-10-31
Active, closed
Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer
NCT03528694Non-muscle-invasive Bladder Cancer
AstraZeneca
Phase 3
1,018
Berlin, Cologne, Duisburg, Hanover, Heidelberg, Marburg, Mettmann, Mühlheim An Der Ruhr
2018-05-14
Rows per page Showing 1–11 of 11
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 28 September 2026. https://priyalifescience.com/clinical-trials-germany/city/mettmann

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 11 of those studies with a site in Mettmann.

How many clinical trials are recruiting in Mettmann?

2 of the 11 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 0 have not yet opened recruitment, 9 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Mettmann), 11 studies
PhaseStudiesRecruitingShare
Phase 37163.6%
Phase 1/22118.2%
Phase 2109.1%
Phase 2/3109.1%

Most active sponsors

Lead sponsors with the most studies (Mettmann)
Lead sponsorStudiesRecruiting
Janssen Research & Development, LLC40
AstraZeneca30
Pfizer21
Eli Lilly and Company10
enGene, Inc.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.